Title : Evaluating the therapeutic potential of Cannabidiol (CBD) in Alzheimer’s disease among adults aged 65 and older: A systematic review
Abstract:
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and a leading cause of morbidity and mortality among adults aged 65 years and older in the United States. Despite the availability of FDA-approved medications, current treatments primarily address symptoms and do not alter disease progression. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has emerged as a potential therapeutic agent due to its anti-inflammatory, neuroprotective, and antioxidant properties. This study aimed to evaluate the potential therapeutic effects and safety of CBD in individuals with Alzheimer’s disease. A systematic literature review was conducted using PubMed, Scopus, and National Institutes of Health databases. Keywords included “cannabidiol,” “Alzheimer’s disease,” “dementia,” and “neurocognitive disorders.” Articles published between 2010 and 2023 were reviewed. A total of 53 studies were identified, with 10 studies meeting inclusion criteria, including preclinical studies, clinical trials, and systematic reviews. Findings suggest that CBD may improve cognitive function, reduce neuroinflammation, and alleviate behavioral symptoms such as anxiety, agitation, and sleep disturbances in individuals with AD. However, evidence remains limited, particularly in human clinical trials. Reported adverse effects include fatigue, gastrointestinal symptoms, and potential drug interactions, particularly with medications metabolized by liver enzymes. These findings highlight CBD as a promising, yet under-researched, therapeutic option for Alzheimer’s disease. Further large-scale clinical trials are needed to establish efficacy, dosing guidelines, and long-term safety. Public health efforts should also consider regulatory, clinical, and educational implications of CBD use among older adult populations.
